Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $5.80.

Several equities research analysts recently weighed in on PSTV shares. D. Boral Capital cut their price objective on shares of Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, January 22nd. Ascendiant Capital Markets dropped their target price on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Zacks Research downgraded shares of Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 11th. Lake Street Capital initiated coverage on shares of Plus Therapeutics in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $2.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $1.00 price objective (down from $2.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd.

Institutional Trading of Plus Therapeutics

A number of hedge funds have recently made changes to their positions in PSTV. Susquehanna International Group LLP acquired a new position in Plus Therapeutics in the third quarter valued at $46,000. Jane Street Group LLC bought a new position in shares of Plus Therapeutics in the 2nd quarter worth about $41,000. Scientech Research LLC acquired a new position in shares of Plus Therapeutics in the 3rd quarter valued at about $100,000. XTX Topco Ltd bought a new stake in shares of Plus Therapeutics during the 4th quarter valued at about $127,000. Finally, State Street Corp grew its stake in Plus Therapeutics by 37.1% during the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after purchasing an additional 127,000 shares during the period. 3.28% of the stock is owned by institutional investors and hedge funds.

Plus Therapeutics Price Performance

Shares of Plus Therapeutics stock opened at $0.30 on Friday. The business has a fifty day simple moving average of $0.34 and a two-hundred day simple moving average of $0.49. The company has a market capitalization of $41.29 million, a price-to-earnings ratio of -0.16 and a beta of 0.79. Plus Therapeutics has a 1 year low of $0.16 and a 1 year high of $2.31.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.